A comparison of nonmyeloablative and reduced-intensity conditioning for allogeneic stem-cell transplantation

Transplantation

Volumn 78, Issue 7, 2004, Pages 1014-1020

  Le Blanc, Katarina ^a   Remberger, Mats ^a   Uzunel, Mehmet ^a   Mattsson, Jonas ^a   Barkholt, Lisbeth ^a   Ringdén, Olle ^a  

^a KAROLINSKA UNIVERSITY HOSPITAL   (Sweden)

Author keywords

Absolute neutrophil count; Allogeneic hematopoietic stem cell transplantation; Antithymocyte globulin; Graft versus host disease; Nonmyeloablative conditioning; Reduced intensity conditioning

Indexed keywords

BUSULFAN; CD19 ANTIGEN; CD3 ANTIGEN; CD45 ANTIGEN; CYCLOPHOSPHAMIDE; CYCLOSPORIN A; FLUDARABINE; METHOTREXATE; MYCOPHENOLIC ACID 2 MORPHOLINOETHYL ESTER; THYMOCYTE ANTIBODY; TREOSULFAN;

ADOLESCENT; ADULT; AGED; ALLOGENEIC HEMATOPOIETIC STEM CELL TRANSPLANTATION; ARTICLE; CHILD; CHIMERA; CONTROLLED STUDY; ERYTHROCYTE TRANSFUSION; FEMALE; GRAFT FAILURE; GRAFT VERSUS HOST REACTION; HEMATOLOGIC MALIGNANCY; HUMAN; IMMUNOSUPPRESSIVE TREATMENT; LEUKOPENIA; MAJOR CLINICAL STUDY; MALE; MORTALITY; POLYMERASE CHAIN REACTION; PRIORITY JOURNAL; SOLID TUMOR; THROMBOCYTE TRANSFUSION; WHOLE BODY RADIATION;

ADOLESCENT; ADULT; AGED; CHILD; FEMALE; GRAFT VS HOST DISEASE; HEMATOPOIETIC STEM CELL TRANSPLANTATION; HUMANS; IMMUNOSUPPRESSION; INCIDENCE; MALE; MIDDLE AGED; RISK FACTORS; TRANSPLANTATION CHIMERA; TRANSPLANTATION CONDITIONING; TRANSPLANTATION, HOMOLOGOUS;

EID: 6344291044     PISSN: 00411337     EISSN: None     Source Type: Journal    
DOI: 10.1097/01.TP.0000129809.09718.7E     Document Type: Article

References (30)

1. Storb R, Thomas ED. Allogeneic bone-marrow transplantation. Immunol Rev 1983; 71: 77-102.
2. Weiden PL, Sullivan KM, Fluornoy N, et al. Antileukemic effect of chronic graft-versus-host disease: Contribution to improved survival after allogeneic marrow transplantation. N Engl J Med 1981; 304: 1529-1533.
3. Horowitz MM, Gale RP, Sondel PM, et al. Graft-versus-leukemia reactions following bone marrow transplantation in humans. Blood 1989; 75: 555-562.
4. Ringdén O, Labopin M, Gluckman E, et al. Graft-versus-leukemia effect in allogeneic marrow transplant recipients with acute leukemia is maintained using cyclosporin A combined with methotrexate as prophylaxis. Bone Marrow Transplant 1996; 18: 921-929.
5. Giralt S, Estey E, Albitar M, et al. Engraftment of allogeneic hematopoietic progenitor cells with purine analog-containing chemotherapy: Harnessing graft-versus-leukemia without myeloablative therapy. Blood 1997; 89: 4531-4536.
6. Slavin S, Nagler A, Naparstek E, et al. Non-myeloablative stem cell transplantation and cell therapy as an alternative to conventional bone marrow transplantation with lethal cytoreduction for the treatment of malignant and non-malignant hematologic diseases. Blood 1998; 91: 756-763.
7. McSweeney PA, Niederwieser D, Shizuru JA, et al. Hematopoietic cell transplantation in older patients with hematologic malignancies: Replacing high-dose cytotoxic therapy with graft-versus-tumor effects. Blood 2001; 97: 3390-3400.
8. Storb R, Deeg HJ, Fisher L, et al. Cyclosporine v. methotrexate for graft-v-host disease prevention in patients given marrow grafts for leukaemia: Long-term follow-up of three controlled trials. Blood 1988; 71: 293-298.
9. Ringdén O, Horowitz MM, Sondel P, et al. Methotrexate, cyclosporine or both to prevent graft-versus-host disease after HLA-identical sibling bone marrow transplants for early leukaemia? Blood 1993; 81: 1094-1101.
10. Mele TS, Halloran PF. The use of mycophenolate mofetil in transplant recipients. Immunopharmacology 2000; 47: 215-245.
11. Bornhäuser M, Schuler U, Pörksen G, et al. Mycophenolate mofetil and cyclosporine as graft-versus-host disease prophylaxis after allogeneic blood stem cell transplantation. Transplantation 1999; 67: 499-504.
12. Meier-Kriesche H-U, Steffen BJ, Hochberg AM, et al. Mycophenolate mofetil versus azathioprine therapy is associated with a significant protection against long-term renal allograft function deterioration. Transplantation 2003; 75: 1341-1346.
13. Hentschke P, Barkholt L, Uzunel M, et al. Low-intensity conditioning of hematopoietic stem cell transplantation in patients with renal and colon carcinoma. Bone Marrow Transplant 2003; 31: 253-261.
14. Schaffer M, Aldener-Cannavá A, Remberger M, et al. Roles of HLA-B, HLA-C and HLA-DPA1 incompatibilities in the outcome of unrelated stem-cell transplantation. Tissue Antigens 2003; 62: 243-250.
15. Ringdén O, Remberger M, Runde V, et al. Peripheral blood stem cell (PBSC) transplantation from unrelated donors: A comparison with marrow transplantation. Blood 1999; 94: 455-464.
16. Niederwieser D, Maris M, Shizuru JA, et al. Low-dose total body irradiation (TBI) and fludarabine followed by hematopoietic cell transplantation (HCT) from HLA-matched or mismatched unrelated donors and postgrafting immunosuppression with cyclosporine and mycophenolate mofetil (MMF) can induce durable complete chimerism and sustained remissions in patients with hematological diseases. Blood 2003; 101: 1620-1629.
17. Ringdén O, Remberger M, Persson U, et al. Similar incidence of graft-versus-host disease using HLA-A, -B and -DR identical unrelated bone marrow donors as with HLA-identical siblings. Bone Marrow Transplant 1995; 15: 619-625.
18. Carlens S, Aschan J, Remberger M, et al. Low-dose cyclosporine of short duration increases the risk of mild and moderate GVHD and reduces the risk of relapse in HLA-identical sibling marrow transplant recipients with leukaemia. Bone Marrow Transplant 1999; 24: 629-635.
19. Ringdén O, Persson U, Johansson SGO, et al. Early diagnosis and treatment of acute human graft-versus-host disease. Transplant Proc 1983; 15: 1490-1494.
20. Svahn B-M, Remberger M, Myrbäck K-E, et al. Home care during the pancytopenic phase after allogeneic hematopoietic stem cell transplantation is advantageous compared to hospital care. Blood 2002; 100: 4317-4324.
21. Ruutu T, Eriksson B, Remes K, et al. Ursodeoxycholic acid for the prevention of hepatic complications in allogeneic stem cell transplantation. Blood 2002; 100: 1977-1983.
22. Hägglund H, Ringdén O, Oman S, et al. A prospective randomized trial of Filgrastim (r-metHuG-CSF) given at different times after unrelated bone marrow transplantation. Bone Marrow Transplant 1999; 24: 831-836.
23. Zetterquist H, Mattsson J, Uzunel M, et al. Mixed chimerism in the B-cell lineage is a rapid and sensitive indicator of minimal residual disease in bone marrow transplant recipients with pre-B-cell acute lymphoblastic leukemia. Bone Marrow Transplant 2000; 25: 843-851.
24. Carlens S, Ringdén O, Remberger M, et al. Risk-factors for chronic graft-versus-host disease after bone marrow transplantation: A retrospective single centre analysis. Bone Marrow Transplant 1998; 22: 755-761.
25. Ljungman P, Loré K, Aschan J, et al. Use of a semi-quantitative PCR for cytomegalovirus DNA as a basis for pre-emptive antiviral therapy in allogeneic bone marrow transplant patients. Bone Marrow Transplant 1996; 17: 583-587.
26. Yu C, Seidel K, Nash RA, et al. Synergism between mycophenolate mofetil and cyclosporine in preventing graft-versus-host disease among lethally irradiated dogs given DLA-nonidentical unrelated marrow grafts. Blood 1998; 91: 2581-2587.
27. Remberger M, Ringdén O, Blau I, et al. No difference in graft-versus-host disease, relapse and survival comparing peripheral stem cells to bone marrow using unrelated donors. Blood 2001; 98: 1739-1745.
28. Remberger M, Storer B, Ringdén O, et al. Association between pretransplant thymoglobulin and reduced non-relapse mortality rate after marrow transplantation from unrelated donors. Bone Marrow Transplant 2002; 29: 391-397.
29. Mielcarek M, Martin PJ, Leisenring W, et al. Graft-versus-host disease after nonmyeloablative versus conventional hematopoietic stem cell transplantation. Blood 2003; 102: 756-762.
30. Cutler C, Ho V, Alyea E, et al. Sirolimus and tacrolimus without methotrexate to prevent graft-vs-host disease after matched, related stem cell transplantation [abstract 38]. Biol Blood Marrow Transplant 2003; 9: 76.